[ad_1]
Researchers in Russia said that combining a drug developed by Oxford University and a British-Swedish pharmaceutical company with Russia’s Sputnik V could increase the effectiveness of the vaccines.
The creators of the Russian coronavirus vaccine “Satellite V“ offered AstraZeneca to combine their products. About that reported company press service on his Twitter page.
AstraZeneca’s current full-dose regimen has shown 62% efficacy, the developers of the Russian vaccine said.
“If you are going to do a new clinical trial, we suggest combining the injection AstraZeneca with “Sputnik V” to increase efficiency. The combination of vaccines can be important in revaccination, “he said in the message.
The current full dose regimen of AstraZeneca resulted in an efficacy of 62%. If they opt for a new clinical trial, we suggest trying a regimen that combines AZ injection with #SputnikV human adenoviral vector to increase efficacy. The combination of vaccines may be important for revaccination.
– Sputnik V (@sputnikvaccine) November 26, 2020
In August, Russian President Vladimir Putin announced the registration of “the world’s first coronavirus vaccine” called “Sputnik V.” The vaccine website states that “it can be used to vaccinate the population in Russia.” The developers claim that a second interim analysis of clinical trial data showed a vaccine efficacy of 91.4% on day 28 after the first dose, and 42 days after the first dose, the efficacy exceeds 95% .
The AZD1222 vaccine, developed by the University of Oxford and the British-Swedish pharmaceutical company AstraZeneca, following the results of intermediate trials in the United Kingdom and Brazil, showed an average efficacy of 70%. reported on the company’s website.
In trials with the first dose (concentration of 2741), when a volunteer received half the dose and approximately one month later the full dose, the vaccine was 90% effective. The second dose (with a concentration of 8,895) showed an efficacy of 62%. In this case, the subjects received two full doses approximately one month apart.
“A combined analysis of two doses (with a concentration of 11,636) showed a mean efficacy in 70% of the cases.“, – said the company.
Clinical trials of the vaccine are underway in the US, Japan, Russia, South Africa, Kenya, and Latin America, and trials are planned in other countries in Europe and Asia. The company hopes to attract up to 60,000 volunteers around the world.
[ad_2]
